logo
  

AstraZeneca Presents Exploratory Sub-analyses From HIMALAYA And TOPAZ-1 Trials

AstraZeneca (AZN.L, AZ) presented data for IMFINZI combinations from the HIMALAYA and TOPAZ-1 Phase III trials. The company said the HIMALAYA results showed a consistent survival benefit with the STRIDE regimen in patients with unresectable liver cancer regardless of baseline liver functional reserve. TOPAZ-1 data showed that IMFINZI plus chemotherapy improved outcomes for biliary tract cancer patients regardless of where their tumor was located or where they lived.

"These important subgroup analyses add to the body of evidence demonstrating the potential for IMFINZI combinations to meaningfully improve outcomes for these patients who are in need of effective and generally well tolerated treatments," said Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT